The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Charles Duncan - Cantor Fitzgerald - Analyst
: Hey, good morning, Rich, Jeff and team. Congratulations on a really nice two q and thanks for taking our questions. I had a couple, first of all, on
AGAMREE. Do you believe that there was any bolus in the first quarter of sales because patients or caregivers were waiting for the drug to be, to
be approved and launched? And then secondarily, I know you don't have any experience with this yet in this market, but what would you anticipate
for summer in terms of, patient and prescriber attendance, if you will?
Question: Charles Duncan - Cantor Fitzgerald - Analyst
: That's helpful. Quick question on FIRDAPSE. Congratulations on the approval of the new higher dose. I had a question about that in terms of the
future adoption and persistency, if you will, for patients, will the new dose impact discontinuations either fewer discontinuations due to increased
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 08, 2024 / 12:30PM, CPRX.OQ - Q2 2024 Catalyst Pharmaceuticals Inc Earnings Call
efficacy or satisfaction? Or will it perhaps result in more discontinuations due to less tolerability? What's your sense of how that adoption of that
higher dose will go for continued use?
Question: Charles Duncan - Cantor Fitzgerald - Analyst
: Okay, last quick question for Rich. Bigger picture strategy. Thinking about some of what you have to bring to the party in terms of, in licensing, do
you have a goal for yet this year? And are you focused more on neuromuscular or perhaps rare epilepsy or other areas of, call it neuro innovation?
Thanks.
Question: Charles Duncan - Cantor Fitzgerald - Analyst
: Thanks, Rich. Nice quarter.
Question: Samantha Semenkow - Citibank - Analyst
: Hi, good morning, and thanks for taking the question. And let me my congratulations on a really nice and strong quarter. So while still really early
in the launch for AGAMREE, I'm wondering how you think about the patient mix will evolve over the next several quarters.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 08, 2024 / 12:30PM, CPRX.OQ - Q2 2024 Catalyst Pharmaceuticals Inc Earnings Call
It seems the percentages that are coming from menthalaza and prednisone thus far really holding steady from what you shared on the first quarter.
And I'm wondering how generic EMFLAVA is fitting into the overall steroid landscape as we'll? And then I have a follow up.
Question: Samantha Semenkow - Citibank - Analyst
: Got it. Great. And then just on FIRDAPSEE, I wonder if you could share just any updates on the process or the timing of the ongoing FIRDAPSEE.
Paragraph four, litigation, and thank you.
Question: Samantha Semenkow - Citibank - Analyst
: Understood. Thanks so much for taking the questions.
Thank you.
Question: Jason Gerberry - Bank of America - Analyst
: Hey, good morning. Thanks for taking my questions. Maybe just first on Biz Dev, are you generally inclined to do more deals funded with cash and
backend success based milestones or talk about maybe appetite to take on some leverage to go after some larger targets that could be more
transformational?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 08, 2024 / 12:30PM, CPRX.OQ - Q2 2024 Catalyst Pharmaceuticals Inc Earnings Call
Question: Jason Gerberry - Bank of America - Analyst
: Okay. And then if I can ask a question about FIRDAPSE, just the growth that you're seeing, it looks like maybe it's two thirds volume, maybe a third
price mix. I assume that that volume is mostly patients that don't have small cell lung as a component of their disease. So is that kind of what you're
seeing in terms of the mix and what's driving this kind of 15% to 20% growth?
Question: Jason Gerberry - Bank of America - Analyst
: Got it, thanks so much, guys.
Question: Leland Gershell - Oppenheimer & Co. Inc - Analyst
: Hi. Good morning, Mike. Congrats on the strong quarter as well. And thanks for taking the question. Just a question again, on AGAMREE these
patients with Duchenne often are not seeing their specialists that frequently.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 08, 2024 / 12:30PM, CPRX.OQ - Q2 2024 Catalyst Pharmaceuticals Inc Earnings Call
If they're medically stable, maybe once every three months, sometimes once every six months. I'm just wondering if you've been seeing patients
coming in to switch to a AGAMREE because it's now available, or are they sort of waiting for their next scheduled deployment to change steroids?
Just sort of an observational question, if you have any perspective there. Thank you.
Question: Leland Gershell - Oppenheimer & Co. Inc - Analyst
: Okay. Thanks very much..
Question: Joseph Catanzaro - Piper Sandler - Analyst
: Great. Hey, everybody, thanks for taking my questions. Maybe, maybe. First one, honing in on for depth a bit more curious. Jeff, what do you
attribute the sort of highest level of new patient starts in the quarter, too. I know you cited a couple things. Maybe you could just speak to that,
which of those you expect to sort of continue, and maybe which factors maybe fade, if at all? That'd be super helpful. And then I have one quick
follow up. Thanks.
Question: Joseph Catanzaro - Piper Sandler - Analyst
: Great. That's helpful. And then my quick follow up, I guess, on portfolio expansion. Rich, I read into maybe some of your comments as there being
sort of inbound inquiries to you guys, wondering if you could characterize the current projects that you're diligent. how many of those, what percent
originated as inbound inquiries versus outbound inquiries? Thanks.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 08, 2024 / 12:30PM, CPRX.OQ - Q2 2024 Catalyst Pharmaceuticals Inc Earnings Call
Question: Joseph Catanzaro - Piper Sandler - Analyst
: Okay, great. That's helpful. And interesting, thanks for taking my questions.
|
